BF02, a recombinant TNFR2 fusion protein, alleviates adjuvant arthritis by regulating T lymphocytes in rats

Acta Pharmacologica Sinica

Volumn 34, Issue 3, 2013, Pages 414-423

  Song, Shan Shan ^a   Huang, Bei ^a   Wang, Qing Tong ^a   Wu, Yu Jing ^a   Fu, Jing Jing ^a   Zhang, Yun Fang ^a   Chang, Yan ^a   Chen, Jing Yu ^a   Wu, Hua Xun ^a   Wang, Di ^a   Zhang, Ling Ling ^a   Wei, Wei ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

adjuvant arthritis; BF02; cytokine; inflammation; methotrexate; T lymphocytes; TNF

Indexed keywords

BF02; COLLAGENASE 3; FC RECEPTOR; INTERLEUKIN 1; INTERLEUKIN 17; INTERLEUKIN 6; L SELECTIN; MESSENGER RNA; METHOTREXATE; OSTEOCLAST DIFFERENTIATION FACTOR; RECOMBINANT PROTEIN; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADJUVANT ARTHRITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANKLE; ARTICLE; CD3+ T LYMPHOCYTE; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; HAND RADIOGRAPHY; HISTOPATHOLOGY; INFLAMMATION; JOINT SWELLING; LYMPHOCYTE FUNCTION; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; REGULATORY T LYMPHOCYTE; SPLEEN; THYMUS; TREATMENT DURATION;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, EXPERIMENTAL; ARTHROGRAPHY; CELL PROLIFERATION; IMMUNOGLOBULIN FC FRAGMENTS; JOINTS; MALE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; RECOMBINANT FUSION PROTEINS; SPLEEN; T-LYMPHOCYTES; THYMUS GLAND;

EID: 84874589746     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2012.171     Document Type: Article

References (41)

1. Jawaheer D, Lum RF, Gregersen PK, Criswell LA. Influence of male sex on disease phenotype in familial rheumatoid arthritis. Arthritis Rheum 2006; 54: 3087-94.
2. Yan Z, Ferucci ED, Geraghty DE, Yang Y, Lanier AP, Smith WP, et al. Resequencing of the human major histocompatibility complex in patients with rheumatoid arthritis and healthy controls in Alaska Natives of Southeast Alaska. Tissue Antigens 2007; 70: 487-94.
3. Nam J, Emery P. Aspects of TNF inhibitor therapy in rheumatoid arthritis. Mod Rheumatol 2010; 20: 325-30.
4. Connor AM, Mahomed N, Gandhi R, Keystone EC, Berger SA. Tumor necrosis factor-alpha modulates protein degradation pathways in RA synovial fibroblasts. Arthritis Res Ther 2012; 14: R62.
5. Bradley JR. TNF-mediated in ammatory disease. J Pathol 2008; 214: 149-60.
6. Wong M, Ziring D, Korin Y, Desai S, Kim S, Lin J, et al. TNFalpha blockade in human diseases: mechanisms and future directions. Clin Immunol 2008; 126: 121-36.
7. Gumà Uriel M. Animal models in rheumatoid arthritis. Reumatol Clin 2008; 4: 129-31.
8. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008; 117: 244-79.
9. Wooley PH, Dutcher J, Widmer MB, Gillis S. Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice. J Immunol 1993; 151: 6602-7.
10. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Eng J Med 1997; 337: 141-7.
11. Hegen M, Keith JC Jr, Collins M, Nickerson-Nutter CL. Utility of animal models for identification of potential therapeutics for rheumatoid arthritis. Ann Rheum Dis 2008; 67: 1505-15.
12. Wang D, Chang Y, Wu Y, Zhang L, Yan S, Xie G, et al. Therapeutic effects of TACI-Ig on rat with adjuvant arthritis. Clin Exp Immunol 2011; 163: 225-34.
13. Wu H, Wei W, Song L, Zhang L, Chen Y, Hu X. Paeoniflorin induced immune tolerance of mesenteric lymph node lymphocytes via enhancing beta 2-adrenergic receptor desensitization in rats with adjuvant arthritis. Int Immunopharmacol 2007; 7: 662-73.
14. Chang Y, Wu Y, Wang D, Wei W, Qin Q, Xie G, et al. Therapeutic effects of TACI-Ig on rats with adjuvant-induced arthritis via attenuating inflammatory responses. Rheumatology (Oxford) 2011; 50: 862-70.
15. Wang QT, Ma YK, Huang B, Liu DD, Wei W. Effect of rhTACI-Ig fusion protein on antigen-specific T cell responses from keyhole limpet haemocyanin challenged mice. Mol Immunol 2011; 49: 380-6.
16. Germolec DR, Nyska A, Kashon M, Kuper CF, Portier C, Kommineni C, et al. Extended histopathology in immunotoxicity testing: interlaboratory validation studies. Toxicol Sci 2004; 78: 107-15.
17. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative CT method. Nat Protoc 2008; 3: 1101-8.
18. Fekete A, Soos L, Szekanecz Z, Szabo Z, Szodoray P, Barath S, et al. Disturbances in B-and T-cell homeostasis in rheumatoid arthritis: suggested relationships with antigen-driven immune responses. J Autoimmun 2007; 29: 154-63.
19. Anderton SM, Fillatreau S. Activated B cells in autoimmune diseases: the case for a regulatory role. Nat Clin Pract Rheumatol 2008; 4: 657-66.
20. Bevaart L, Vervoordeldonk MJ, Tak PP. Evaluation of therapeutic targets in animal models of arthritis: how does it relate to rheumatoid arthritis? Arthritis Rheum 2010; 62: 2192-205.
21. Tran CN, Lundy SK, Fox DA. Synovial biology and T cells in rheumatoid arthritis. Pathophysiology 2005; 12: 183-9.
22. Panayi GS. B cells: a fundamental role in the pathogenesis of rheumatoid arthritis? Rheumatology (Oxford) 2005; 44: 3-7.
23. Feldmann M, Maini RN. Anti-TNF therapy, from rationale to standard of care: what lessons has it taught us? J Immunol 2010; 185: 791-4.
24. Choo-Kang BS, Hutchison S, Nickdel MB, Bundick RV, Leishman AJ, Brewer JM, et al. TNF-blocking therapies: an alternative mode of action? Trends Immunol 2005; 26: 518-22.
25. Raza K, Buckley CE, Salmon M, Buckley CD. Treating very early rheumatoid arthritis. Best Pract Res Clin Rheumatol 2006; 20: 849-63.
26. Calmon-Hamaty F, Combe B, Hahne M, Morel J. Lymphotoxin α stimulates proliferation and pro-inflammatory cytokine secretion of rheumatoid arthritis synovial fibroblasts. Cytokine 2011; 53: 207-14.
27. Chiang EY, Kolumam GA, Yu X, Francesco M, Ivelja S, Peng I, et al. Targeted depletion of lymphotoxin-alpha-expressing TH1 and TH17 cells inhibits autoimmune disease. Nat Med 2009; 15: 766-73.
28. Schneider K, Potter KG, Ware CF. Lymphotoxin and LIGHT signaling pathways and target genes. Immunol Rev 2004; 202: 49-66.
29. Dayer Schneider J, Seibold I, Saxer-Sekulic N, Paredes BE, Saurer L, Mueller C. Lack of TNFR2 expression by CD4+ T cells exacerbates experimental colitis. Eur J Immunol 2009; 39: 1743-53.
30. Pinto LG, Cunha TM, Vieira SM, Lemos HP, Verri WA Jr, Cunha FQ, et al. IL-17 mediates articular hypernociception in antigen-induced arthritis in mice. Pain 2010; 148: 247-56.
31. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005; 6: 1123-32.
32. Rou A, Mrgritescu C, Stepan A, Muetescu A, Ene M. IL-17 patterns in synovium, serum and synovial fluid from treatment-naïve, early rheumatoid arthritis patients. Rom J Morphol Embryol 2012; 53: 73-80.
33. Sarkar S, Fox DA. Targeting IL-17 and Th17 cells in rheumatoid arthritis. Rheum Dis Clin North Am 2010; 36: 345-66.
34. Hasan E, Olusi S, Al-Awadhi A, Mokaddem K, Sharma P, George S. Effects of rituximab treatment on the serum concentrations of vitamin D and interleukins 2, 6, 7, and 10 in patients with rheumatoid arthritis. Biologics 2012; 6: 31-5.
35. Vincenti MP, Brinckerhof f CE. Transcriptional regulation of collagenase (MMP-1, MMP-13) genes in arthritis: integration of complex signaling pathways for the recruitment of gene-speci?c transcription factors. Arthritis Res 2002; 4: 157-64.
36. Bettelli E, Oukka M, Kuchroo VK. TH-17 cells in the circle of immunity and autoimmunity. Nat Immunol 2007; 8: 345-50.
37. Walker MR, Kasprowicz DJ, Gersuk VH, Benard A, Van Landeghen M, Buckner JH, et al. Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25-T cells. J Clin Invest 2003; 112: 1437-43.
38. Chavele KM, Ehrenstein MR. Regulatory T-cells in systemic lupus erythematosus and rheumatoid arthritis. FEBS Lett 2011; 585: 3603-10.
39. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008; 59: 762-84.
40. Yang T, Wang Z, Wu F, Tan J, Shen Y, Li E, et al. A variant of TNFR2-Fc fusion protein exhibits improved efficacy in treating experimental rheumatoid arthritis. PLoS Comput Biol 2010; 6: e1000669.
41. Salgado E, Gómez-Reino JJ. The risk of tuberculosis in patients treated with TNF antagonists. Expert Rev Clin Immunol 2011; 7: 329-40.